SVB Leerink Maintains Outperform on Avidity Biosciences, Lowers Price Target to $50
SVB Leerink maintains Avidity Biosciences (NASDAQ:RNA) with a Outperform and lowers the price target from $53 to $50.
Avidity Biosciences Q1 EPS $(0.71) Down From $(0.64) YoY, Sales $1.79M Down From $2.70M YoY
Avidity Biosciences (NASDAQ:RNA) reported quarterly losses of $(0.71) per share. This is a 10.94 percent decrease over losses of $(0.64) per share from the same period last year. The company reported $1.79 million in
Avidity Biosciences: Q4 Earnings Insights
Avidity Biosciences (NASDAQ:RNA) reported its Q4 earnings results on Tuesday, March 1, 2022 at 04:05 PM.
Here's what investors need to know about the announcement.
12 Health Care Stocks Moving In Wednesday’s After-Market Session
Gainers
Cognition Therapeutics (NASDAQ:CGTX) shares rose 14.9% to $6.62 during Wednesday's after-market session. The market value of their outstanding shares is at $145.8 million.
10 Biggest Price Target Changes For Friday
Keybanc boosted the price target on Broadcom Inc. (NASDAQ: AVGO) from $575 to $710. Broadcom shares fell 0.9% to close at $583.42 on Thursday.
SVB Leerink Maintains Outperform on Avidity Biosciences, Raises Price Target to $53
SVB Leerink analyst Joseph Schwartz maintains Avidity Biosciences (NASDAQ:RNA) with a Outperform and raises the price target from $36 to $53.
Avidity Biosciences Q3 EPS $(0.68) Down From $(0.31) YoY, Sales $2.16M Up From $1.75M YoY
Avidity Biosciences (NASDAQ:RNA) reported quarterly losses of $(0.68) per share. This is a 119.35 percent decrease over losses of $(0.31) per share from the same period last year. The company reported $2.16 million in
Avidity Biosciences Announces FDA Grants Fast Track Designation To AOC 1001 For The Treatment Of Myotonic Dystrophy Type 1
Avidity Biosciences, Inc. (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the U.S. Food and
